Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 4Myelodysplastic Syndromes 3Urinary Bladder Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Leukemia, Myelomonocytic, Chronic 2Hodgkin Disease 2Hematologic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Tumor Virus Infections 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Peritoneal Neoplasms 1Osteosarcoma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

130-nm albumin-bound paclitaxel 5Oxaliplatin 4Leucovorin 4Gemcitabine 4Fluorouracil 4Carboplatin 4Albumin-Bound Paclitaxel 4Paclitaxel 3Cisplatin 3pembrolizumab 2Pemetrexed 2Cetuximab 2Bevacizumab 2tremelimumab 1napabucasin 1irinotecan sucrosofate 1durvalumab 1cc-486 1Taxes 1Irinotecan 1EC regimen 1CP protocol 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Pancreatic Ductal × cc-486 × Clear all
NCT01478685 2019-11-12

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Celgene

Phase 1 Completed
169 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence, Tumor Virus Infections, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡